captopril has been researched along with glucagon-like peptide 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, L; Baron, AD; Broyde, A; Fernandez, R; Liu, Q; Parkes, DG | 1 |
| Abouelkheir, M; El-Metwally, TH | 1 |
2 other study(ies) available for captopril and glucagon-like peptide 1
| Article | Year |
|---|---|
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Captopril; Cardiotonic Agents; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Hyperglycemia; Hypertension, Renal; Hypoglycemic Agents; Insulin Resistance; Kidney Diseases; Male; Peptides; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary; Venoms | 2010 |
Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enalapril; Female; Glucagon-Like Peptide 1; Humans; Hypertension; Linagliptin; Peptidyl-Dipeptidase A; Protein Binding; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate | 2019 |